Daiichi Sankyo and Merck report phase 2 trial results for lung cancer drug
Investing.com -- ONWARD Medical reported EUR1.2 million in revenue for the first half of 2025, a significant increase from EUR0.2 million in the same period last year, driven by the sale of 30 ARC-EX systems in the United States.
The company saw a clear acceleration in sales between the first and second quarters of 2025, with units sold doubling from 10 in Q1 to 20 in Q2. This growth demonstrates early commercial traction for the ARC-EX system, which was launched in December 2024.
ONWARD’s shares declined nearly 3% on Tuesday as the company released its financial results.
Management reported positive user satisfaction and successful integration of the ARC-EX system into rehabilitation workflows, which reinforces confidence in the product’s clinical relevance and commercial potential. The company also noted strong early demand and expects further acceleration in Q3 as adoption expands beyond pilot centers.
The full-year consensus revenue target of approximately USD7.8 million, representing around 200 units, remains achievable but will require a substantial increase in sales during the second half of the year. To meet this target, ONWARD needs wider site activation and faster conversion of clinical interest into sales.
Operating loss for the first half of 2025 reached EUR20.0 million, compared to EUR18.7 million in the first half of 2024. This increase aligns with expectations and reflects continued investment in commercial infrastructure, clinical operations, and regulatory activities as the company transitions to a commercial-stage organization.
As of June 2025, ONWARD had EUR40.9 million in cash, up from EUR32.1 million at the end of 2024. This provides sufficient funding to support the ongoing US launch and pipeline development through 2025. The company’s equity increased to EUR27.7 million, while interest-bearing debt declined to EUR14.2 million.
ONWARD continues to manage its balance sheet conservatively, maintaining strategic and financing flexibility ahead of key commercial and clinical milestones expected in 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.